- ¥1tn
- ¥997bn
- ¥497bn
Japan's Kirin looks to sell Kentucky bourbon brand for $1 billion, FT reports (updated)
Brief: Kura Oncology And Kyowa Kirin Announce First Patient Dosed In Pivotal Phase 3 Komet-017 Trial
Factbox: Asian and European drugmakers' branded drugs imported to the US market
Table: Kyowa Kirin 6-MTH group results (IFRS)
Brief: Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data
Kura Oncology gains as FDA accepts marketing application for blood cancer drug
Table: Kyowa Kirin -Q1 group results (IFRS)
Brief: Garuda Therapeutics Closes $50 Million Series A-1 Financing To Advance Off-The-Shelf Blood Stem Cell Therapies
Table: Kyowa Kirin -2024 group results (IFRS)
Table: Kyowa Kirin -2024 parent results
Brief: Kura Oncology And Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial
Brief: Alphameld Corporation Expands Collaboration With Kyowa Kirin For Enterprise-Wide Access To Drug Discovery Platform
Kura slides as licensing deal seen as reducing chances of buyout
Kura to partner with Kyowa Kirin for blood cancer drug; shares fall
Kura Oncology to partner with Kyowa Kirin for blood cancer therapy (updated)
Kura Oncology to partner with Kyowa Kirin for blood cancer therapy
Brief: Kura Oncology And Kyowa Kirin Announce Strategic Collaboration To Develop And Commercialize Ziftomenib In Acute Leukemias
Brief: Kyowa Kirin Announces Changes In Top Leadership Positions To Strengthen Operations As A Global Specialty Pharmaceutical Company
Brief: Kyowa Kirin Says Masashi Miyamoto To be Named As Chairman And CEO